Sandoz rolls out Europe’s first Stelara biosimilar autoinjector
Swiss biosimilars specialist Sandoz (SIX: SDZ) has launched what it says is the first autoinjector presentation of a biosimilar to Stelara (ustekinumab) in Europe, bolstering its presence in the region’s rapidly expanding immunology market.
The product, branded as Pyzchiva (ustekinumab), was developed by Samsung Bioepis (KRX: 207940) and is being commercialized by Sandoz under a 2023 agreement that grants it exclusive marketing rights in Europe, the UK, USA and Brazil.
Pyzchiva has already been launched in 23 countries across the continent. The device, based on SHL Medical’s Molly platform, is designed to improve patient comfort, reduce injection pain, and enhance treatment adherence—key concerns in chronic inflammatory diseases such as plaque psoriasis, psoriatic arthritis and Crohn’s disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze